Shingles vaccine market to reach $12.9 billion by 2034 due to aging population and awareness

From Globe Newswire: 2025-01-22 07:05:00

The shingles vaccine market was valued at USD 4.9 billion in 2024 and is expected to grow at a CAGR of 10.1% from 2025 to 2034. Factors driving growth include an aging population, improved reimbursement, and increased awareness of shingles prevention. Efforts to educate the public about shingles risks have boosted vaccine adoption, particularly among older adults. Health organizations emphasize vaccination benefits in reducing complications and chronic pain, encouraging proactive health measures.

Shingrix leads the shingles vaccine market, generating USD 4.2 billion in revenue in 2023. Its recombinant formulation offers durable protection, especially for older adults, reducing the need for frequent boosters. Recombinant vaccines dominate the market, demonstrating 90% protection efficacy and extended immunity duration, eliminating the need for repeated doses. North America’s shingles vaccine market reached USD 2.7 billion in 2023, driven by high awareness levels and supportive healthcare policies, with recommendations for vaccination widely adopted for adults aged 50 and older.

Major players in the shingles vaccine market include GSK plc., Merck & Co., and SK bioscience. Global Market Insights offers detailed industry reports and consultation services, providing clients with actionable market data for strategic decision-making. Their reports cover key industries such as chemicals, technology, renewable energy, and biotechnology, designed through a proprietary research methodology to aid in strategic planning and growth initiatives.



Read more at Globe Newswire: Shingles Vaccine Market to hit USD 12.9 billion by 2034,